Sugi Predict

Sugi Predict / Compounds / SCHEMBL1840156

SCHEMBL1840156

SCHEMBL1840156

c1ccc2c(c1)ccn2-c1cc[nH]n1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CDC7 O00311 1/20 0.49
▸ CDK2 P24941 1/20 0.49
▸ ROCK1 Q13464 1/20 0.49
▸ PRKD3 O94806 1/20 0.46
▸ PRKCG P05129 1/20 0.46
▸ PRKCB P05771 1/20 0.46
▸ PRKCA P17252 1/20 0.46
▸ PRKACA P17612 1/20 0.46
▸ PRKACG P22612 1/20 0.46
▸ PRKACB P22694 1/20 0.46
▸ PRKCH P24723 1/20 0.46
▸ PRKCI P41743 1/20 0.46
▸ PRKCE Q02156 1/20 0.46
▸ PRKCQ Q04759 1/20 0.46
▸ PRKCZ Q05513 1/20 0.46
▸ PRKCD Q05655 1/20 0.46
▸ PRKD1 Q15139 1/20 0.46
▸ BIRC5 O15392 1/20 0.43
▸ MAPT P10636 3/20 0.40
▸ MKNK1 Q9BUB5 4/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30822643 0.77 GAA (0.38) PRKD3PRKCGPRKCBPRKCAPRKACA
SCHEMBL20368880 0.74 CDC7 (0.58) CDC7CDK2ALDH1A1
SCHEMBL6594548 0.74 CDC7 (0.47) CDC7CDK2ROCK1PRKD3PRKCG
SCHEMBL30128160 0.73 MAPT (0.35) MAPT
Hydrochloric Acid SCHEMBL30128372 0.72 MAPT (0.35) MAPT
SCHEMBL16339578 0.71 CA12 (0.43) PRKD3PRKCGPRKCBPRKCAPRKACA
SCHEMBL30043505 0.71 CA12 (0.43) PRKD3PRKCGPRKCBPRKCAPRKACA
SCHEMBL31107087 0.70 CDC7 (0.60) CDC7CDK2ROCK1PRKD3PRKCG
SCHEMBL524138 0.70 CDC7 (0.60) CDC7CDK2ROCK1PRKD3PRKCG
SCHEMBL29388549 0.70 CDC7 (0.60) CDC7CDK2ROCK1PRKD3PRKCG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230340412-A1 Expansion Of Peripheral Blood Lymphocytes (PBLS) From Peripheral Blood IOVANCE BIOTHERAPEUTICS INC (US) 2023-10-26 — — US claimed
EP-0944623-B1 SUBSTITUTED PYRAZOLE-3-YL BENZAZOLES BASF AG (DE) 2004-09-01 — — EP claimed
US-6232470-B1 AGRICULTURE BASF AKTIENGESELLSCHAFT (DE) 2001-05-15 — — US claimed
EP-0944623-A2 SUBSTITUTED PYRAZOLE-3-YL BENZAZOLES BASF AKTIENGESELLSCHAFT (DE) 1999-09-29 — — EP claimed
WO-1998027090-A2 SUBSTITUTED PYRAZOLE-3-YL BENZAZOLES BASF AKTIENGESELLSCHAFT (DE) 1998-06-25 — — WO claimed
US-20260144870-A1 PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY IOVANCE BIOTHERAPEUTICS, INC. (US) 2026-05-28 — — US disclosed
US-20260124242-A1 EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES FROM LIQUID TUMORS AND THERAPEUTIC USES THEREOF IOVANCE BIOTHERAPEUTICS INC (US) 2026-05-07 — — US disclosed
US-12473532-B2 Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy IOVANCE BIOTHERAPEUTICS, INC. (US) 2025-11-18 — — US disclosed
WO-2025006811-A1 METHODS FOR CULTURING IMMUNE CELLS LYELL IMMUNOPHARMA, INC. (US) 2025-01-02 — — WO disclosed
US-20240392245-A1 EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES FROM LIQUID TUMORS AND THERAPEUTIC USES THEREOF IOVANCE BIOTHERAPEUTICS INC (US) 2024-11-28 — — US disclosed
CN-118660954-A Method for culturing immune cells 莱尔免疫制药公司 2024-09-17 — — CN disclosed
EP-4423249-A1 METHODS FOR CULTURING IMMUNE CELLS Lyell Immunopharma, Inc. (US) 2024-09-04 — — EP disclosed
US-6482774-B1 Substituted (4-brompyrazole-3-yl) benzazoles BASF AKTIENGESELLSCHAFT (DE) 2002-11-19 — — US disclosed
US-6232470-B1 AGRICULTURE BASF AKTIENGESELLSCHAFT (DE) 2001-05-15 — — US disclosed
US-6232470-B1 AGRICULTURE BASF AKTIENGESELLSCHAFT (DE) 2001-05-15 — — US disclosed
EP-0944623-A2 SUBSTITUTED PYRAZOLE-3-YL BENZAZOLES BASF AKTIENGESELLSCHAFT (DE) 1999-09-29 — — EP disclosed
EP-0944623-A2 SUBSTITUTED PYRAZOLE-3-YL BENZAZOLES BASF AKTIENGESELLSCHAFT (DE) 1999-09-29 — — EP disclosed
WO-1998027090-A3 SUBSTITUTED PYRAZOLE-3-YL BENZAZOLES BASF AG (DE) 1998-09-17 — — WO disclosed
WO-1998027090-A2 SUBSTITUTED PYRAZOLE-3-YL BENZAZOLES BASF AKTIENGESELLSCHAFT (DE) 1998-06-25 — — WO disclosed
WO-1998027090-A2 SUBSTITUTED PYRAZOLE-3-YL BENZAZOLES BASF AKTIENGESELLSCHAFT (DE) 1998-06-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230340412-A1 Expansion Of Peripheral Blood Lymphocytes (PBLS) From Peripheral Blood LTK, LIFR, PBK CDC7 2898/4885CDK2 3970/4885ROCK1 4653/4885
US-20260124242-A1 EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES FROM LIQUID TUMORS AND THERAPEUTIC USES THEREOF PBK, LTK, BLK CDC7 1544/4885CDK2 338/4885ROCK1 2775/4885
US-20260144870-A1 PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY PBK, ITK, IL2 CDC7 723/4885CDK2 722/4885ROCK1 1758/4885
US-20240392245-A1 EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES FROM LIQUID TUMORS AND THERAPEUTIC USES THEREOF PBK, MALT1, BCL9L CDC7 3677/4885CDK2 3472/4885ROCK1 4110/4885
US-12473532-B2 Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy ICOS, PBK, IL2 CDC7 4311/4885CDK2 4818/4885ROCK1 4344/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.